Schrodinger (NASDAQ:SDGR) Upgraded at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of Schrodinger (NASDAQ:SDGR) to a hold rating in a research report released on Monday morning,Zacks.com reports.

SDGR has been the topic of several other research reports. KeyCorp dropped their price objective on shares of Schrodinger from $32.00 to $30.00 and set an “overweight” rating on the stock in a report on Monday, July 14th. Wall Street Zen upgraded shares of Schrodinger from a “sell” rating to a “hold” rating in a report on Friday, September 26th. Citigroup lowered shares of Schrodinger from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $35.00 to $20.00 in a report on Friday, August 15th. Barclays began coverage on shares of Schrodinger in a report on Thursday, August 14th. They issued an “overweight” rating and a $25.00 target price on the stock. Finally, Morgan Stanley lowered their target price on shares of Schrodinger from $28.00 to $19.00 and set an “equal weight” rating on the stock in a report on Monday, August 18th. Four research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $26.57.

Schrodinger Trading Up 5.7%

Shares of NASDAQ SDGR opened at $21.21 on Monday. The firm’s 50-day moving average price is $19.66 and its 200-day moving average price is $21.43. Schrodinger has a 1-year low of $16.60 and a 1-year high of $28.47. The firm has a market capitalization of $1.56 billion, a P/E ratio of -8.55 and a beta of 1.74.

Schrodinger (NASDAQ:SDGR) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.24. Schrodinger had a negative net margin of 76.22% and a negative return on equity of 45.70%. The firm had revenue of $54.76 million for the quarter, compared to analyst estimates of $52.03 million. During the same quarter in the prior year, the business earned ($0.66) earnings per share. The business’s quarterly revenue was up 15.7% compared to the same quarter last year. Equities research analysts forecast that Schrodinger will post -2.37 EPS for the current year.

Institutional Investors Weigh In On Schrodinger

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Greenwood Capital Associates LLC increased its stake in Schrodinger by 2.7% in the 1st quarter. Greenwood Capital Associates LLC now owns 23,139 shares of the company’s stock valued at $457,000 after buying an additional 612 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in Schrodinger by 29.9% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,956 shares of the company’s stock valued at $58,000 after buying an additional 680 shares during the last quarter. Bank of Montreal Can increased its stake in Schrodinger by 5.8% in the 2nd quarter. Bank of Montreal Can now owns 15,941 shares of the company’s stock valued at $321,000 after buying an additional 879 shares during the last quarter. Farther Finance Advisors LLC increased its stake in Schrodinger by 347.4% in the 2nd quarter. Farther Finance Advisors LLC now owns 1,284 shares of the company’s stock valued at $26,000 after buying an additional 997 shares during the last quarter. Finally, Tema Etfs LLC increased its stake in Schrodinger by 6.3% in the 2nd quarter. Tema Etfs LLC now owns 17,493 shares of the company’s stock valued at $352,000 after buying an additional 1,036 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Schrodinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.